10Elms LLP’s iShares Biotechnology ETF IBB Stock Holding History

10Elms LLP’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$342K	Hold	2,025	–	–	0.22%	68
2025 Q4	$342K	Hold	2,025	–	–	0.31%	60
2025 Q3	$292K	Hold	2,025	–	–	0.26%	67
2025 Q2	$256K	Hold	2,025	–	–	0.24%	66
2025 Q1	$259K	Hold	2,025	–	–	0.26%	62
2024 Q4	$268K	Buy	+2,025	New	+$285K	0.28%	60

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

10Elms LLP's IBB Position: Q1 2026 in Review

10Elms LLP held its iShares Biotechnology ETF (IBB) position steady in Q1 2026 at 2,025 shares worth $342K. The position accounts for 0.22% of the portfolio, ranked #68.

10Elms LLP first reported a position in IBB in Q4 2024 and has held it in 6 quarters since. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

10Elms LLP held 2,025 shares of iShares Biotechnology ETF worth $342K as of Q1 2026.
10Elms LLP left its iShares Biotechnology ETF share count unchanged in Q1 2026.
iShares Biotechnology ETF made up 0.22% of 10Elms LLP's portfolio in Q1 2026, its #68 holding.
10Elms LLP first reported a position in iShares Biotechnology ETF in Q4 2024 and has held it in 6 quarters since.
917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on 10Elms LLP's 13F filing for Q1 2026, filed 15 May 2026.